In the clinical presentations of occupational musculoskeletal disorders, there is a leading role for the vertebrogenic syndromes caused by degenerative and dystrophic changes, spondyloarthrosis in particular. Therefore, the use of chondroprotectors is a mandatory component of combination pathogenetic treatment. A total of 87 patients with spondyloarthrosis received annually paravertebral and intramuscular Alflutop in the Clinic of Occupational Diseases, Novosibirsk Research Institute of Hygiene, over 5 years. The results were analyzed; the drug was shown to be effective in reducing the severity of pain syndrome and the number of annual exacerbations and in increasing motor activity, depending on the route of its administration.